Theriva Biologics, Inc. (NYSEAMERICAN:TOVX) Short Interest Update

Theriva Biologics, Inc. (NYSEAMERICAN:TOVX) was the target of a significant drop in short interest during the month of May. As of May 15th, there was short interest totaling 4,060,180 shares, a drop of 52.3% from the April 30th total of 8,509,923 shares. Currently, 12.1% of the shares of the company are sold short. Based on an average daily trading volume, of 3,052,240 shares, the short-interest ratio is currently 1.3 days.

Theriva Biologics Trading Down 0.6%

Theriva Biologics stock traded down $0.00 during trading on Monday, reaching $0.28. 1,495,708 shares of the company were exchanged, compared to its average volume of 16,817,598. The stock’s 50 day simple moving average is $0.29 and its two-hundred day simple moving average is $0.24. The company has a market capitalization of $9.51 million, a P/E ratio of -0.01 and a beta of 1.11. The company has a debt-to-equity ratio of 0.11, a current ratio of 1.63 and a quick ratio of 1.63. Theriva Biologics has a 52-week low of $0.16 and a 52-week high of $0.86.

Theriva Biologics (NYSEAMERICAN:TOVX) last issued its earnings results on Tuesday, May 5th. The company reported ($0.05) earnings per share (EPS) for the quarter.

Hedge Funds Weigh In On Theriva Biologics

A hedge fund recently bought a new stake in Theriva Biologics stock. Two Sigma Investments LP acquired a new position in shares of Theriva Biologics, Inc. (NYSEAMERICAN:TOVX) during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 61,837 shares of the company’s stock, valued at approximately $25,000. Two Sigma Investments LP owned about 0.64% of Theriva Biologics as of its most recent filing with the SEC. 6.17% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Separately, Maxim Group raised Theriva Biologics from a “hold” rating to a “buy” rating and set a $1.00 target price on the stock in a report on Tuesday, March 31st. One equities research analyst has rated the stock with a Buy rating, According to MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $1.00.

About Theriva Biologics

Theriva Biologics, Inc, a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. The company’s lead product candidate is VCN-01, a clinical stage oncolytic human adenovirus that is in a Phase 2 clinical study for the treatment of pancreatic cancer; a Phase 1 clinical study for the treatment of retinalblastoma; a Phase 1 clinical study for the treatment of head and neck squamous cell carcinoma; and a Phase 1 clinical study for the treatment of solid tumors.